Tailored Versus Standard Hydration to Prevent Acute Kidney Injury After Percutaneous Coronary Intervention: Network Meta-Analysis.
Acute Kidney Injury
/ chemically induced
Contrast Media
/ adverse effects
Fluid Therapy
/ adverse effects
Humans
Incidence
Infusions, Intravenous
Network Meta-Analysis
Percutaneous Coronary Intervention
/ adverse effects
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
contrast‐induced acute kidney injury
coronary angiography
hydration
percutaneous coronary intervention
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
06 07 2021
06 07 2021
Historique:
pubmed:
26
6
2021
medline:
30
10
2021
entrez:
25
6
2021
Statut:
ppublish
Résumé
Background Contrast-induced acute kidney injury (CI-AKI) is a serious complication after percutaneous coronary intervention. The mainstay of CI-AKI prevention is represented by intravenous hydration. Tailoring infusion rate to patient volume status has emerged as advantageous over fixed infusion-rate hydration strategies. Methods and Results A systematic review and network meta-analysis with a frequentist approach were conducted. A total of 8 randomized controlled trials comprising 2312 patients comparing fixed versus tailored hydration strategies to prevent CI-AKI after percutaneous coronary intervention were included in the final analysis. Tailored hydration strategies included urine flow rate-guided, central venous pressure-guided, left ventricular end-diastolic pressure-guided, and bioimpedance vector analysis-guided hydration. Primary endpoint was CI-AKI incidence. Safety endpoint was incidence of pulmonary edema. Urine flow rate-guided and central venous pressure-guided hydration were associated with a lower incidence of CI-AKI compared with fixed-rate hydration (odds ratio [OR], 0.32 [95% CI, 0.19-0.54] and OR, 0.45 [95% CI, 0.21-0.97]). No significant difference in pulmonary edema incidence was observed between the different hydration strategies.
Identifiants
pubmed: 34169747
doi: 10.1161/JAHA.121.021342
pmc: PMC8403299
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e021342Références
Minerva Cardioangiol. 2019 Oct;67(5):380-391
pubmed: 31527583
Epidemiol Health. 2019;41:e2019013
pubmed: 30999733
Am J Med. 1997 Nov;103(5):368-75
pubmed: 9375704
J Am Coll Cardiol. 2018 Jun 26;71(25):2880-2889
pubmed: 29929610
JACC Cardiovasc Interv. 2014 Jan;7(1):1-9
pubmed: 24456715
J Physiol. 1931 Jun 6;72(1):49-61
pubmed: 16994199
Lancet. 2014 May 24;383(9931):1814-23
pubmed: 24856027
Circulation. 2011 Sep 13;124(11):1260-9
pubmed: 21844075
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
J Interv Cardiol. 2020 Feb 11;2020:7292675
pubmed: 32116474
PLoS One. 2019 Feb 20;14(2):e0212650
pubmed: 30785955
Biometrics. 1996 Jun;52(2):536-44
pubmed: 8672702
BMC Med Res Methodol. 2015 Jul 31;15:58
pubmed: 26227148
JACC Cardiovasc Interv. 2012 Jan;5(1):90-7
pubmed: 22230154
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
Circulation. 2020 Jul 14;142(2):150-160
pubmed: 32468837
Int Urol Nephrol. 2019 Oct;51(10):1815-1822
pubmed: 31332700
J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9
pubmed: 15464318
Lancet. 2017 Apr 1;389(10076):1312-1322
pubmed: 28233565
Lancet. 1988 May 7;1(8593):1033-5
pubmed: 2896877
PLoS One. 2017 Feb 2;12(2):e0168726
pubmed: 28151965
J Am Heart Assoc. 2021 Jul 6;10(13):e021342
pubmed: 34169747
JACC Cardiovasc Interv. 2020 Sep 14;13(17):2065-2074
pubmed: 32912462
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Circ Cardiovasc Interv. 2017 Apr;10(4):
pubmed: 28404621
Circulation. 2002 May 14;105(19):2259-64
pubmed: 12010907
Rev Cardiovasc Med. 2003;4 Suppl 5:S3-9
pubmed: 14668704
Crit Care. 2017 Aug 28;21(1):225
pubmed: 28844205
J Am Coll Cardiol. 2013 Jun 4;61(22):2242-8
pubmed: 23721921
N Engl J Med. 1994 Nov 24;331(21):1416-20
pubmed: 7969280
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Coll Cardiol. 2009 Feb 17;53(7):589-596
pubmed: 19215833
J Pharmacol Exp Ther. 1978 Jul;206(1):198-206
pubmed: 660550
Interv Cardiol Clin. 2020 Jul;9(3):299-309
pubmed: 32471671
BMJ. 2014 Sep 24;349:g5630
pubmed: 25252733
Can J Cardiol. 2016 Feb;32(2):247-55
pubmed: 26277092
J Cardiovasc Med (Hagerstown). 2016 Jul;17(7):530-7
pubmed: 26702595
Clin Infect Dis. 2011 May;52(9):e162-93
pubmed: 21460264
Lancet. 2019 Nov 23;394(10212):1949-1964
pubmed: 31777389
Res Synth Methods. 2012 Jun;3(2):161-76
pubmed: 26062088
JACC Cardiovasc Interv. 2019 Oct 14;12(19):1877-1888
pubmed: 31521648
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1432-1444
pubmed: 32553331
Drugs. 1990;39 Suppl 4:10-21; discussion 22-4
pubmed: 2354670
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
JACC Cardiovasc Interv. 2016 Jan 11;9(1):89-96
pubmed: 26685074
J Clin Epidemiol. 2018 Jan;93:36-44
pubmed: 29051107